Complement Anaphylatoxins C3a And C5a in Diabetic and Non-Diabetic Iraqi COVID-19 patients

Abstract

CoV-2 infection has become a global issue in healthcare since December 2019. According to our findings, diabetes raises the likelihood and severity of COVID-19 disease in 2019. High blood sugar was found to reduce immunity and worsen COVID-19 while it is linked to several other risk factors. With COVID-19, the study will assess the levels of C3a and C5a in diabetes and non-diabetic patients. This study included 120 covid-19 patients (60 diabetic and 60 non-diabetic). Serum levels were measured in patients and the results showed that the mean levels of C3a and C5a were higher in non-diabetic Covid-19 patients (451.82±108.94 and 215.70±48.37pg/ml respectively) compared with those with diabetes (357.88±41.22 and 188.86±33.98pg/ml respectively) with a significant difference between the two groups (p < 0.001).